cyclooxygenase-2 (COX-2) specific inhibitor

From Aaushi
Jump to navigation Jump to search

Contraindications

* safe in patients with aspirin-exacerbated respiratory disease[12]

Adverse effects

Drug interactions

Mechanism of action

Notes

December 23, 2004: The U.S. Food and Drug Administration (FDA) issued a public health advisory concerning use of non-steroidal anti-inflammatory drug products (NSAIDs) including those known as COX-2 selective agents.[5]

More general terms

More specific terms

Additional terms

References

  1. Prescriber's Letter 7(10):55 2000
  2. Prescriber's Letter 8(6):31-32 2001
  3. Journal Watch 23(13):103, 2003 Spiegel BMR et al, Ann Intern Med 138:795, 2003
  4. Prescriber's Letter 11(11): 2004 Safety of COX-2 Inhibitors and Their Place in Therapy Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=201102&pb=PRL (subscription needed) http://www.prescribersletter.com
  5. Jump up to: 5.0 5.1 http://www.fda.gov/cder/drug/advisory/nsaids.htm
  6. Prescriber's Letter 12(2): 2005 Update on the Safety and Use of COX-2 Inhibitors and Traditional NSAIDs Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210202&pb=PRL (subscription needed) http://www.prescribersletter.com
  7. Prescriber's Letter 12(3): 2005 COX-2 Inhibitor Safety: An Update Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210301&pb=PRL (subscription needed) http://www.prescribersletter.com
  8. Jump up to: 8.0 8.1 Journal Watch 25(6):46, 2005 Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med. 2005 Jan 24;165(2):189-92. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15668365
  9. Prescriber's Letter 12(5): 2005 FDA Announces Important Changes and Additional Warnings for COX-2s and NSAIDs Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210505&pb=PRL (subscription needed) http://www.prescribersletter.com
  10. FDA MedWatch COX-2 Selective (includes Bextra, Celebrex, and Vioxx) and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) http://www.fda.gov/medwatch/SAFETY/2005/safety05.htm#NSAID
  11. Jump up to: 11.0 11.1 Medical Knowledge Self Assessment Program (MKSAP) 16 American College of Physicians, Philadelphia 2012
  12. Jump up to: 12.0 12.1 12.2 Morales DR et al. Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials. J Allergy Clin Immunol 2014 Jul; 134:40 PMID: https://www.ncbi.nlm.nih.gov/pubmed/24388008